VRCA offering history
Every offering-related filing in Verrica Pharmaceuticals Inc.’s recent SEC record — registrations (announced capacity) kept separate from pricing documents (executed sales). Reviewed 530 filings back to Dec 17, 2015.
| Date | Filing | What it means | |
|---|---|---|---|
| Dec 23, 2025 | 424B3 → | UPDATE | Prospectus update — often a resale registration, not necessarily new capital |
| Dec 23, 2025 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Dec 15, 2025 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Nov 24, 2025 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Mar 25, 2025 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Mar 11, 2025 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Nov 21, 2024 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Nov 20, 2024 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| May 15, 2024 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Jul 26, 2023 | 8-K → | EXECUTED | Unregistered share sale disclosed (8-K item 3.02) |
| Feb 22, 2023 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Feb 21, 2023 | FWP → | MARKETING | Free-writing prospectus — offering being marketed |
| Dec 19, 2022 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Dec 19, 2022 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Nov 7, 2022 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Jul 1, 2022 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Jun 29, 2022 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Mar 23, 2021 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Mar 22, 2021 | 424B5 → | EXECUTED | Shelf takedown priced — shares or notes (small-caps: usually shares; open the filing to confirm) |
| Mar 25, 2020 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Mar 13, 2020 | S-3 → | REGISTERED | S-3 registration — capacity to sell shares, not a sale yet |
| Jun 15, 2018 | 424B4 → | EXECUTED | Final prospectus — offering priced (typical for IPOs and marketed share deals) |
| Jun 14, 2018 | EFFECT → | EFFECTIVE | SEC declared a registration effective — selling can begin |
| Jun 5, 2018 | S-1/A → | REGISTERED | S-1/A registration — capacity to sell shares, not a sale yet |
| May 22, 2018 | S-1 → | REGISTERED | S-1 registration — capacity to sell shares, not a sale yet |
Two honest limits. (1) A 424B takedown can price shares or notes— EDGAR’s metadata doesn’t say which, so open the document: large investment-grade filers use these mostly for bond deals (no dilution), small-caps mostly for shares. (2) At-the-market (ATM) programs sell shares gradually and individual sales are not separately filed — the visible footprint is the enabling shelf and its 424B5; actual ATM share counts surface later in the 10-Q/10-K share count. Educational information from public filings, not investment advice.
VRCA offering FAQ
When did VRCA last execute an offering?
Per SEC filings, Verrica Pharmaceuticals Inc.'s most recent priced offering document is a 8-K filed 2025-11-24. Note a 424B takedown can price shares or notes (debt) — the linked document says which.
When did VRCA last announce or register an offering?
The most recent registration is a S-3 filed 2025-12-15. A registration is capacity to sell shares — not a sale.
Does an offering always mean dilution?
Registered direct offerings and shelf takedowns issue new shares and dilute existing holders. Resale registrations (424B3/B7) let existing holders sell and do not create new shares. Secondary sales by insiders also do not dilute. Each row here is labeled with what it is.